Perioperative therapies for urological cancers

Junichi Inokuchi, Akira Yokomizo, Naotaka Nishiyama, Hiroshi Kitamura, Masatoshi Eto, Hiroyuki Nishiyama, Yoshihiko Tomita

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Although surgery with curative intent is critical for management of many localized cancers, multimodal therapy including neoadjuvant and adjuvant therapy has been introduced to increase the effectiveness of local control of surgery and prolong survival. However, strong evidence supporting the utility of such multimodal therapy is limited. The utility of perioperative chemotherapy has been extensively investigated in bladder cancer, and several randomized controlled trials have indicated the benefit of neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Regrettably, perioperative therapy for other urological cancers is controversial; therefore, no definitive conclusions have been drawn. Recently, the number of trials has rapidly increased due to the development of immune checkpoint inhibitors, used alone or in combination with other modalities. In this review, we summarize the current status and supporting evidence for perioperative therapies such as neoadjuvant and adjuvant therapies for urological cancers, including prostate cancer, urothelial cancer and renal cell carcinoma.

Original languageEnglish
Pages (from-to)357-367
Number of pages11
JournalJapanese journal of clinical oncology
Issue number4
Publication statusPublished - Apr 1 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Perioperative therapies for urological cancers'. Together they form a unique fingerprint.

Cite this